Re: Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering
"That's it, in a nut shell. Are ZFNs perfect? No. I bet you were under the impression that that mattered. It doesn't."
I've said this very thing here in the past in the context of discussing BLUE who has a tremendous off-target issue, but also that the fact that it (apparently) does not matter much applies to CRISPR too.
I have no problem with what you say in this post, but unless you have almost everybody on the board blocked or you don't read it regularly I find it difficult to believe that you don't conclude that most here do think just like the OP I responded to.